Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases
Marie-Hélène Lafeuille, MA, Jonathan Gravel, MSc, Amanda Grittner, MA, Patrick Lefebvre, MA, Lorie A. Ellis, PhD, Scott McKenzie, MD
Prostate cancer is the most frequently diagnosed noncutaneous malignancy in males and is a leading cause of cancer-related morbidity and mortality among men in the United States.1,2 The American Cancer Society has estimated that approximately 238,600 new cases of prostate cancer will be diagnosed in 2013, and that approximately 29,700 men will die of the disease.3
Although patients with cancer represent only 1% of commercially insured patients, 10% of commercial health insurance expenditures is spent on this patient population.1 Throughout 2012, the conversation about mounting business pressures on oncology practices to address this discrepancy has been dominated by 3 topics—the viability of accountable care organizations (ACOs) as a model for delivery of oncology care, payer efforts to standardize cancer care through the implementation of oncology clinical pathways, and how these emerging care delivery systems would affect oncology
New Oncology Care Delivery Payment Models to Enhance Care Efficiency
Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy
Renal cell carcinoma (RCC) comprises 92% of all kidney cancers and has a poor prognosis, with approximately 10% of patients with metastatic disease surviving beyond 5 years.1 In 2006, the economic burden of metastatic RCC (mRCC) was estimated to be up to $1.6 billion worldwide and has since grown annually.2 A recent review reported that the economic burden of RCC in the United States ranges from $600 million to $5.19 billion, with annual per-patient medical costs of between $16,488 and $43,805.3 Furthermore, these costs will likely increase with the expanded
Cost and Effectiveness of Therapies for Advanced Kidney Cancer: The Need for Economic and Clinical Analyses
Abby Swanson Kazley, PhD, Kit N. Simpson, DrPH, Annie Simpson, PhD, Edward Jauch, MD, Robert J. Adams, MD
Stroke remains a leading cause of disability and is the fourth leading cause of death in the United States.1,2 Approximately 780,000 strokes occur in the United States annually; in 2004, stroke accounted for 1 of every 16 deaths.3 The burden of stroke is especially high in South Carolina, which is central within the so-called Stroke Belt.4-7 The Stroke Belt is an 11-state region in the southeastern United States that has been characterized as having a particularly high incidence of stroke.
Stroking This South Carolina Model: Will It Play in Peoria?
A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention
David Gregory, MPA, Dennis J. Scotti, PhD, MBA, Gregory de Lissovoy, PhD, MPH, Igor Palacios, MD, Simon Dixon, MD, Brijeshwar Maini, MD, William O’Neill, MD
More than 1 in 3 American adults have at least one type of cardiovascular disease, which is the leading cause of death in the United States for men and women.1 The total annual burden of heart disease is estimated to be $312.6 billion in combined direct and indirect costs.1 In addition to an overall annual cost of more than $34 billion,2 heart failure is one of the main medical conditions necessitating acute hemodynamic support.
Careful Selection of Candidates for Percutaneous Ventricular Assist Device Is Crucial
Patricia Sacco, MPH, RPh, Gorana Capkun-Niggli, PhD, Xin Zhang, MS, Rosemary Jose, PhD, Michael F. Murphy, MD, PhD
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, with cognitive and behavioral impairments of varying degrees that are associated with distinct physical features.1 This neurodevelopmental disorder is caused by the silencing of a single X-linked gene, the fragile X mental retardation 1 gene, and hence manifests primarily in males.
Rarity, Disease Heterogeneity, and a Pathway for Estimating Economic Burden
Budget Impact Model: Epigenetic Assay Can Help Avoid Unnecessary Repeated Prostate Biopsies and Reduce Healthcare Spending
Wade Aubry, MD, Robert Lieberthal, PhD, Arnold Willis, MD, Grant Bagley, MD, Simon M. Willis III, MS, Andrew Layton, BA
Prostate cancer is the most frequently detected cancer in men, and 1 of 6 men will be diagnosed with prostate cancer during their lifetime based on Medicare enrollment data.1 In the United States, approximately 19 million men annually are screened by prostate-specific antigen (PSA) testing,2 resulting in approximately 4.7 million abnormal PSA test results (≥4.0 ng/mL)3 leading to approximately 1.3 million biopsy procedures.4 According to the National Cancer Institute, 241,740 men are diagnosed with prostate cancer annually, and 28,170 prostate
Molecular Epigenetic Tests Can Improve Clinical Outcomes While Reducing Healthcare Costs
The Opportunity for Health Plans to Improve Quality and Reduce Costs by Embracing Primary Care Medical Homes
The large and growing cost of healthcare, which amounted to 17.9% of the gross domestic product in 2011,1 will continue to be a burden for all payers in the US healthcare system, not only for states that are struggling to meet Medicaid costs and the federal government’s requirements, but also for private health plans that serve commercial, Medicare Advantage, and Medicaid beneficiaries.2,3 Costs will continue to grow as millions more people become newly insured because of the Patient Protection and Affordable Care Act (ACA).
Enhancing Health Outcomes and Quality of Care with the Medical Home Model in Primary Care
Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets
Anke-Peggy Holtorf, PhD, MBA, Diana Brixner, RPh, PhD, Brandon Bellows, PharmD, Abdulkadir Keskinaslan, MD, MBA, MPH, Joseph Dye, RPh, PhD, Gary Oderda, PharmD, MPH
With increasing access and utilization of healthcare, resources become more restricted, and prioritization in healthcare becomes unavoidable. Health economics and outcomes research (HEOR) is a discipline that is used to complement traditional clinical development information (ie, efficacy, safety, quality) to guide decision makers regarding patient access to specific drugs and services. HEOR has advanced considerably in methodology and in quantity over the past several decades.
Health Economics and Outcomes Research Data Key in Coverage Decisions of New Medications
Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care
Annette Powers, PharmD, MBA, Claudio Faria, PharmD, MPH, Eunice Chang, PhD, Dasha Cherepanov, PhD, Jeffrey A. Bourret, PharmD, MS, BCPS, FASHP
Myelodysplastic syndrome (MDS) encompasses a heterogeneous group of clonal disorders of hematopoiesis and is characterized by dysplastic morphology of marrow and blood cells, ineffective hematopoiesis, and peripheral blood cytopenias.1,2 Most patients with MDS experience progressive worsening of blood cytopenias, with an increasing need for transfusion.2 These patients also have an increasing number of potentially fatal infections and hemorrhagic complications.2 The more advanced and severe the MDS is, the greater the risk that the disease will progress to a
Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome
Page 6 of 11
Results 51 - 60 of 109
Results 51 - 60 of 109